AIM™ nanoparticle (direct injection) is an injectable pharmaceutical product of aAPC nanoparticles decorated with tumor-specific antigen loaded HLA molecules and antiCD28 stimulatory molecules. Based on specific size and bio-distribution characteristics, the AIM™ nanoparticles (direct injection) have the ability to engage tumor antigen-specific T cell populations at multiple sites (Lymph Node, Lymphatic System, peripheral blood, tumor).

Following administration in pre-clinical models, AIM™ nanoparticle (direct injection) have demonstrated the ability to stimulate tumor-infiltrating lymphocytes (TILS), which are known to mediate killing in human tumors.